Iminodibenzyl is an impurity in commercial preparations of Carbamazepine. It is the final product of antidepressant imipramine oxidation. Iminodibenzyl is a building block of many antipsychotic drugs. Iminodibenzyl derivatives demonstrated anti-leishmanial activity. Iminodibenzyl, in combination with 3-methyl-2-benzothiazolinonehydrazone hydrochloride are used as chromogenic co-substrates for quantification of hydrogen peroxide and glucose.

Carbamazepine is an analgesic, anti-epileptic agent that is FDA approved for the treatment of epilepsy, trigeminal neuralgia. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Commonly reported side effects of carbamazepine include: dizziness, drowsiness, nausea, ataxia, and vomiting. Carbamazepine is a potent inducer of hepatic CYP1A2, 2B6, 2C9/19, and 3A4 and may reduce plasma concentrations of concomitant medications mainly metabolized by CYP1A2, 2B6, 2C9/19, and 3A4 through induction of their metabolism, like Boceprevir, Cyclophosphamide, Aripiprazole, Tacrolimus, Temsirolimus and others.